

APC anti-human IFN- γ Antibody

| | |
|--------------------------|---|
| Catalog# / Size | 502511 / 25 tests 502512 / 100 tests |
| Clone | 4S.B3 |
| Regulatory Status | RUO |
| Other Names | Interferon- γ , Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF), IFN-g, IFN-gamma |
| Isotype | Mouse IgG1, κ |
| Description | Interferon- γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN- γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN- γ can upregulate MHC class I and II antigen expression by antigen-presenting cells. |

Product Details

| | |
|-------------------------------|---|
| Verified Reactivity | Human |
| Reported Reactivity | Chimpanzee, Baboon, Cynomolgus, Rhesus |
| Antibody Type | Monoclonal |
| Host Species | Mouse |
| Immunogen | Partially purified, native human IFN- γ |
| Formulation | Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA) |
| Preparation | The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions. |
| Storage & Handling | The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze. |
| Application | ICFC - Quality tested |
| Recommended Usage | Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is 5 μ l per million cells in 100 μ l staining volume or 5 μ l per 100 μ l of whole blood. |
| Excitation Laser | Red Laser (633 nm) |
| Application Notes | <p>ELISA or ELISPOT Detection⁵: The biotinylated 4S.B3 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified NIB42 antibody (Cat. No. 502402/502404) or purified MD-1 antibody (Cat. No. 507502/507513) as the capture antibody.</p> <p>Flow Cytometry^{3,4,6-8}: The fluorochrome-labeled 4S.B3 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ-producing cells within mixed cell populations.</p> <p>Additional reported applications (for the relevant formats) include: neutralization^{1,2}, Western blotting, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated tissue sections, and immunocytochemistry. The 4S.B3 antibody can neutralize the bioactivity of natural or recombinant IFN-γ.</p> <p>Note: For testing human IFN-γ in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. No. 430101 to 430106) are specially developed and recommended.</p> |

Application References

1. Meager A, *et al.* 1984. *J. Interferon Res.* 4:619. (Neut)
2. Meager A, 1987. *Lymphokines and Interferons: A Practical Approach*. IRL Press Ltd, Oxford, p. 105. (Neut)
3. Sester M, *et al.* 2002. *J. Virol.* 76:3748. (ICFC)
4. Infante-Duarte C, *et al.* 2000 *J. Immunol.* 165:6107. (ICFC)
5. Goodier M, *et al.* 2000. *J. Immunol.* 165:139. (ELISA)

6. Chen H, *et al.* 2005. *J. Immunol.* 175:591. (ICFC)
7. Smeltz RB, 2007. *J. Immunol.* 178:4786. (ICFC)
8. Iwamoto S, *et al.* 2007. *J. Immunol.* 179:1449. (ICFC) [PubMed](#)
9. Yoshino N, *et al.* 2000. *Exp. Anim. (Tokyo)* 49:97. (ICFC)

Product Citations

1. Shao L, *et al.* 2021. *Cell Death Discov.* 7:145. [PubMed](#)
2. Li M, *et al.* 2021. *J Clin Invest.* 131:.. [PubMed](#)
3. Goetzmann J, *et al.* 2014. *Proc Natl Acad Sci U S A.* 111:8873. [PubMed](#)
4. Wang H, *et al.* 2022. *Front Immunol.* 13:852436. [PubMed](#)
5. Cook CP, *et al.* 2022. *Cell Rep Med.* 3:100715. [PubMed](#)
6. Devalraju KP, *et al.* 2021. *PLoS One.* 16:e0257185. [PubMed](#)
7. Chandran A, *et al.* 2022. *Cell Rep Med.* 3:100557. [PubMed](#)
8. Su W, *et al.* 2022. *Front Immunol.* 13:952338. [PubMed](#)
9. Harshe RP, *et al.* 2020. *Nat Commun.* 11:5894. [PubMed](#)
10. Norian L, *et al.* 2009. *Cancer Res.* 69:3086. [PubMed](#)
11. Pandey A, *et al.* 2020. *Nat Commun.* 3.392361111. [PubMed](#)
12. Evans RDR, *et al.* 2020. *Nat Commun.* 3.491666667. [PubMed](#)
13. Wang Y, *et al.* 2021. *Sci Rep.* 1.429861111. [PubMed](#)
14. Longhi M, *et al.* 2014. *PLoS One.* 9:87956. [PubMed](#)
15. Du Y, *et al.* 2022. *Nat Commun.* 13:231. [PubMed](#)
16. Zeng Q, *et al.* 2022. *Front Immunol.* 13:740805. [PubMed](#)
17. Cai J, *et al.* 2021. *eLife.* 10:00. [PubMed](#)
18. Baban B, *et al.* 2021. *JCI Insight.* 6:00. [PubMed](#)
19. Faust HJ, *et al.* 2020. *J Clin Invest.* 130:5493. [PubMed](#)
20. Port JR, *et al.* 2020. *J Virol.* 94:.. [PubMed](#)
21. Anderson AE, *et al.* 2022. *NPJ Regen Med.* 7:6. [PubMed](#)
22. Guo S, *et al.* 2021. *Stem Cells Int.* 2021:9989790. [PubMed](#)
23. Draganov DD, *et al.* 2019. *J Transl Med.* 17:100. [PubMed](#)
24. Ni J, *et al.* 2020. *Immunity.* 52(6):1075-1087.e8. [PubMed](#)
25. Liu W, *et al.* 2022. *Bio Protoc.* 12:e4285. [PubMed](#)
26. Zhang X, *et al.* 2017. *J Immunol.* 10.4049/jimmunol.1602183. [PubMed](#)
27. Du Q, *et al.* 2018. *J Immunol.* 201:533. [PubMed](#)
28. Ge C, *et al.* 2020. *Cell Reports.* 29(13):4236-4244.e3.. [PubMed](#)
29. Roybal KT *et al.* 2016. *Cell.* 167(2):419-432. [PubMed](#)
30. Waight JD, *et al.* 2018. *Cancer Cell.* 33:1033. [PubMed](#)
31. O'Donoghue GP, *et al.* 2021. *Proc Natl Acad Sci U S A.* 118:.. [PubMed](#)
32. Boutboul D, *et al.* 2018. *J Clin Invest.* 128:3071. [PubMed](#)
33. Fang Y, *et al.* 2021. *J Clin Invest.* 131:00:00. [PubMed](#)
34. Pahl JHW, *et al.* 2018. *Cancer Immunol Res.* 0.609027778. [PubMed](#)
35. Wei J, *et al.* 2019. *J Immunother Cancer.* 7:209. [PubMed](#)
36. Prakash MD, *et al.* 2021. *PLoS One.* 16:e0247492. [PubMed](#)
37. Zhou Z, *et al.* 2022. *J Gastrointest Oncol.* 13:732. [PubMed](#)
38. Festag J, *et al.* 2020. *Mol Ther Nucleic Acids.* 1.330555556. [PubMed](#)
39. Wang Y, *et al.* 2021. *Cell Reports.* 36(6):109516. [PubMed](#)
40. Tian X, *et al.* 2015. *J Immunol.* 194:3873. [PubMed](#)
41. Shen C, *et al.* 2021. *BMC Med.* 19:283. [PubMed](#)
42. Yang C, *et al.* 2019. *Nat Commun.* 10:3931. [PubMed](#)
43. Tesch S, *et al.* 2020. *Sci Rep.* 10:21312. [PubMed](#)

RRID

AB_315236 (BioLegend Cat. No. 502511)
 AB_315237 (BioLegend Cat. No. 502512)

Antigen Details

| | |
|---------------------------|---|
| Structure | Cytokine; dimer; 20-25 kD (Mammalian) |
| Bioactivity | Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APC |
| Cell Sources | CD8 ⁺ and CD4 ⁺ T cells, NK cells |
| Cell Targets | T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts |
| Receptors | IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1) |
| Cell Type | Tregs |
| Biology Area | Cell Biology, Immunology, Neuroinflammation, Neuroscience |
| Molecular Family | Cytokines/Chemokines |
| Antigen References | <ol style="list-style-type: none"> 1. Fitzgerald K, <i>et al.</i> Eds. 2001. <i>The Cytokine FactsBook.</i> Academic Press, San Diego. 2. De Maeyer E, <i>et al.</i> 1992. <i>Curr. Opin. Immunol.</i> 4:321. 3. Farrar M, <i>et al.</i> 1993. <i>Annu. Rev. Immunol.</i> 11:571. 4. Gray P, <i>et al.</i> 1987. <i>Lymphokines</i> 13:151. |

Regulation Upregulated by IL-2, FGF-basic, EGF; downregulated by vitamin D3 or DMN; labile at pH2

Gene ID [3458](#)

Related Protocols


[Surface and Intracellular Cytokine Staining for Flow Cytometry - Video](#)

[Intracellular Flow Cytometry Staining Protocol](#)

Other Formats

PE anti-human IFN- γ , APC anti-human IFN- γ , FITC anti-human IFN- γ , Biotin anti-human IFN- γ , Purified anti-human IFN- γ , Alexa Fluor® 488 anti-human IFN- γ , Alexa Fluor® 647 anti-human IFN- γ , Alexa Fluor® 700 anti-human IFN- γ , Pacific Blue™ anti-human IFN- γ , PerCP/Cyanine5.5 anti-human IFN- γ , APC/Cyanine7 anti-human IFN- γ , PE/Cyanine7 anti-human IFN- γ , Brilliant Violet 421™ anti-human IFN- γ , Brilliant Violet 570™ anti-human IFN- γ , Brilliant Violet 605™ anti-human IFN- γ , Brilliant Violet 650™ anti-human IFN- γ , Brilliant Violet 711™ anti-human IFN- γ , Brilliant Violet 785™ anti-human IFN- γ , Brilliant Violet 510™ anti-human IFN- γ , PE/Dazzle™ 594 anti-human IFN- γ , APC/Fire™ 750 anti-human IFN- γ , PerCP anti-human IFN- γ , Brilliant Violet 750™ anti-human IFN- γ , KIRAVIA Blue 520™ anti-human IFN- γ Antibody, Spark NIR™ 685 anti-human IFN- γ Antibody

Product Data



PMA+ionomycin stimulated (6 hours) human peripheral blood lymphocytes (in the presence of monensin) were stained with CD3 PE, then fixed with Fixation Buffer (Cat# 420801), and permeabilized with Permeabilization Wash Buffer (Cat# 421002). Cells were then stained with IFN- γ (clone 4S.B3) APC (top) or mouse IgG1, κ APC isotype control (bottom).

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587